- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.04. | FDA to review Regeneron's sBLA for aflibercept injection 8mg | ||
| 17.04. | Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline | ||
| 17.04. | Big pharma pushes for European policy change as tariffs loom | ||
| 17.04. | FDA approves Neurelis' nasal spray for seizures | ||
| 17.04. | ACIP recommends GSK's RSV vaccine for at-risk adults 50 to 59 | ||
| 16.04. | Trump order eases Medicare price negotiation for small molecule drugs | ||
| 16.04. | Glycomine raises $115m to advance rare disease therapy into Phase IIb | ||
| 16.04. | WHO member states agree on treaty to fight future pandemics | ||
| 16.04. | Podcast: What's next for the pharma tariffs? | ||
| 16.04. | The GLP-1 drug shortage is over. What's next for the compounders? | ||
| 16.04. | EC authorises Eisai and Biogen's lecanemab for Alzheimer's | ||
| 16.04. | Mural shuts down lead programme and slashes 90% of staff | ||
| 16.04. | Irish pharmaceutical exports to US soar amid tariff concerns | ||
| 16.04. | The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033 | ||
| 16.04. | Boehringer and Cue Biopharma to develop autoimmune therapies | ||
| 15.04. | Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts? | ||
| 15.04. | ESCMID Global 2025: Climate-informed infectious disease risk management | ||
| 15.04. | Coherus divests Udenyca franchise to Intas for up to $558.4m | ||
| 15.04. | How collaborative partnerships are driving progress in transformative cell and gene therapies (CGTs) | ||
| 15.04. | Ironwood's shares sink as FDA demands new trial for lead drug | ||
| 15.04. | Valneva's single-dose chikungunya vaccine authorised in Brazil | ||
| 15.04. | Reveal Genomics and Ona link on ONA-255 development for cancer | ||
| 14.04. | Verve Therapeutics' shares jump by more than 26% on Lilly-partnered gene therapy data | ||
| 14.04. | Pfizer drops obesity pill development after liver injury report | ||
| 14.04. | COPD market projected to grow to $30.2bn in the 7MM by 2033 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
